The Cochlear (ASX:COH) share price tumbles 7% despite dividend boost

The implantable hearing device developer released it FY21 results this morning.

| More on:
Boxer falls down in the ring, indicating a share price performance low.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Cochlear Ltd (ASX: COH) share price is tumbling in late morning trade, down 7.4% to $237.08 per share.

This comes despite the ASX healthcare company meeting guidance in its full year results for the 2021 financial year, released earlier today. And despite a boost to its dividend payout.

What dividend did Cochlear announce?

The Cochlear share price is falling even though the company boosted its full-year dividend by 59%, to $2.55.

Management was able to return some cash to investors' pockets after Cochlear saw sales revenue grow 10% in FY21, reaching $1.49 billion. Underlying net profit of $236.7 million was also up 54% year-on-year. And profits beat guidance, which management had forecast would come in the range of $225–245 million.

That, however, appears not to have satisfied many investors, with Cochlear dropping heavily even as the S&P/ASX 200 Index (ASX: XJO) edges up 0.3%.

So, why is the Cochlear share price tumbling?

My Foolish colleague James Mickleboro may have nailed the answer to that question before markets opened today, writing:

While Cochlear's profit was within its guidance range, it appears to have fallen short of the market's expectations. According to CommSec, the analyst consensus was a net profit after tax of $245.5 million. This could potentially weigh on the Cochlear share price today.

It's not uncommon for investors to punish stocks that fall short of consensus expectations.

Cochlear share price snapshot

Even with today's large drop, the Cochlear share price remains a standout performer in 2021, up 28% year-to-date. That's more than double the gains posted by the ASX 200 this calendar year.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended Cochlear Ltd. The Motley Fool Australia has recommended Cochlear Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Business people discussing project on digital tablet.
Healthcare Shares

Where will CSL shares be in 5 years?

Would it be a good time to buy and hold this fallen giant? Let's find out.

Read more »

Six smiling health workers pose for a selfie.
Healthcare Shares

Up 657% in a year, 4DMedcial shares rocketing another 20% today on big US news

ASX investors can’t get enough of 4DMedical shares today. Let’s see why.

Read more »

Health professional working on his laptop.
Healthcare Shares

NIB shares edge higher on profit update

Let's see why this private health insurer is in the news today.

Read more »

Researchers and doctors with futuristic 3d hologram overlay for body anatomy or dna in hospital clinic.
Healthcare Shares

Bell Potter names the best ASX healthcare shares to buy in 2026

Healthy returns could be on offer with these shares according to the broker.

Read more »

man cupping ear as if to listen closely, rumour, cochlear
Healthcare Shares

Why is everyone talking about Telix shares this week?

Let's see why this biotech stock has been on the move this week.

Read more »

Medical workers examine an xray or scan in a hospital laboratory.
Healthcare Shares

This ASX stock is going parabolic, and I think it's still a buy

4DMedical shares are up nearly 500% in 2025, but improving revenue visibility suggests the growth story may not be over.

Read more »

ecommerce asx shares represented by santa doing online shopping on laptop
Healthcare Shares

Looking for ideas before Christmas? These 2 ASX shares stand out to me

Two ASX shares at opposite ends of the market are catching my attention as the year draws to a close.

Read more »

A doctor or medical expert in COVID protection adjusts her glasses, indicating growth or strong share price movement in ASX medical, biotech and health companies
Opinions

Forget CSL shares, I'd buy this booming biotech stock instead

This ASX biotech stock has caught my eye this year.

Read more »